Tag: MONOGRAPH

  • SRT1720

    Selective SIRT1 activator

    An imidazothiazole SIRT1 activator; the structural lineage compound from which SRT2104 was developed.

    Abstract

    SRT1720 (CAS 925434-55-5; molecular formula C22H19N5OS2; molecular weight 433.55) is an imidazothiazole SIRT1 activator developed at Sirtris Pharmaceuticals as a potent (approximately 1000-fold over resveratrol) and selective sirtuin 1 activator. Mechanism is allosteric SIRT1 activation comparable to SRT2104. Mouse studies demonstrated lifespan extension in diet-induced obese mice, improved metabolic parameters, and reduced age-related pathology. The compound was the foundation for the broader Sirtris drug discovery program; SRT2104 was developed as a more drug-like successor with better human pharmacokinetics. SRT1720 is used preferentially in academic research where the established mouse pharmacology is valuable. Plasma half-life is approximately 8 to 10 hours.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Imuracetam

    Imidazole-fused pyrrolidinone racetam

    An obscure imidazole-substituted racetam from early Soviet pharmacology with sparse published literature.

    Abstract

    Imuracetam is an imidazole-substituted piracetam analog reported in early Soviet nootropic pharmacology literature. Published data are extremely sparse; the compound never advanced to clinical trials in any jurisdiction and is not approved as a medicine in any market. The structural innovation is fusion of an imidazole ring to the pyrrolidinone scaffold, intended to enhance lipophilicity and modulate the cholinergic profile. Mechanism is incompletely characterized but is thought to overlap with piracetam pharmacology (membrane fluidity, indirect cholinergic, weak AMPA modulation). The compound is occasionally available from research chemical vendors but the chain of custody and analytical characterization on commercial samples is generally unverifiable. Investigators using imuracetam should obtain analytical confirmation of identity and purity before use. There is no human pharmacokinetic data, no formal safety profile, and no dose-finding data in any species. This monograph is provided for completeness of the racetam class survey and as a cautionary entry: not every compound with a “racetam” suffix has substantive published support, and obscurity is itself a research consideration.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Mexidol (Emoxypine)

    Pyridine antioxidant

    A Russian-developed pyridine antioxidant (2-ethyl-6-methyl-3-hydroxypyridine succinate) widely prescribed in Russia for cerebrovascular and cognitive disorders.

    Abstract

    Mexidol (Emoxypine succinate; 2-ethyl-6-methyl-3-hydroxypyridine succinate; CAS 127464-43-1) is a pyridine-class antioxidant developed in the Soviet Union in the 1980s and approved in Russia for cerebrovascular insufficiency, cognitive impairment, and acute neurological events including stroke. The compound combines a 3-hydroxypyridine antioxidant (emoxypine) with succinate as the metabolic energy substrate. Mechanism is multimodal: free radical scavenging, membrane phospholipid stabilization, succinate-driven mitochondrial substrate provision under conditions of compromised respiratory chain function, and modest GABA-A allosteric modulation. The compound is administered orally or by IV/IM injection in clinical use. The Russian clinical evidence base is extensive (used in tens of thousands of patients) but Western-grade randomized trials with standard endpoints are limited.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • IGF-1 LR3

    Long Arg3 IGF-1 analog

    A long-acting analog of IGF-1 with N-terminal extension and Arg3 substitution that reduces IGFBP binding and extends plasma half-life.

    Abstract

    IGF-1 LR3 (Long R3 IGF-1; CAS 946870-92-4; molecular weight 9111) is a recombinant analog of human IGF-1 with two structural modifications: a 13-residue N-terminal extension derived from the methionyl-N-terminal region of porcine GH, and substitution of arginine for glutamic acid at position 3. Both modifications reduce binding to IGF binding proteins (IGFBPs), which extends the plasma half-life and increases free bioavailable IGF-1 activity at IGF-1 receptors. The compound was originally developed for cell culture applications (mammalian cell growth media); research-grade availability supports investigational use. Pharmacokinetics: plasma half-life approximately 20 to 30 hours (versus 12 to 15 hours for native IGF-1). The compound is sold as a research chemical at concentrations typically 1 mg/mL.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Lion’s Mane (Hericium erinaceus)

    Medicinal mushroom / NGF inducer

    A medicinal mushroom containing hericenones and erinacines with documented NGF induction and modest cognitive enhancement in mild cognitive impairment.

    Abstract

    Hericium erinaceus (Lion’s Mane mushroom) is a medicinal mushroom containing hericenones (in the fruiting body) and erinacines (in the mycelium), both classes of which induce nerve growth factor (NGF) expression in vitro and in vivo. NGF is critical for cholinergic neuron survival and function. Additional studies suggest peripheral nerve regeneration applications and modest anxiolytic effects. The compound is sold as both fruiting body extracts and mycelium-on-grain products; the latter contains erinacines but also significant residual grain (rice, oats) which has led to controversy about active constituent content.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Thymogen

    Synthetic dipeptide immunomodulator

    A synthetic dipeptide (Glu-Trp) developed in Russia as an immunomodulator for infectious and post-surgical immune support.

    Abstract

    Thymogen is the dipeptide L-glutamyl-L-tryptophan, developed in Russia at the Institute of Bioregulation and Gerontology. The compound was identified through fractionation of thymalin (bovine thymus extract) as one of the active components. Thymogen is approved in Russia and several former Soviet states for infectious diseases, post-surgical immune support, and hematopoietic recovery after chemotherapy. Mechanism includes modest T-cell maturation effects and cytokine modulation. Administered intranasally or intramuscularly.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • N-Acetyl-L-Tyrosine

    Acetylated tyrosine

    An N-acetylated form of L-tyrosine with claimed superior bioavailability that has not been validated in pharmacokinetic studies.

    Abstract

    N-Acetyl-L-Tyrosine (NALT) is an N-acetylated form of L-tyrosine sold as a dietary supplement with claims of improved bioavailability and CNS penetration compared with L-tyrosine itself. Pharmacokinetic studies in humans show that NALT is poorly converted to free tyrosine by tissue deacetylases (the bulk is excreted as NALT in urine without contributing to tyrosine pools). The compound is therefore likely to be inferior to L-tyrosine on a milligram basis for catecholamine support applications, despite vendor claims. Investigators should generally use L-tyrosine itself.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Magnesium Glycinate

    Magnesium-glycine chelate

    A magnesium chelate with glycine, with superior bioavailability and minimal gastrointestinal effects compared with magnesium oxide.

    Abstract

    Magnesium glycinate (magnesium bisglycinate) is a chelated magnesium salt where magnesium is bound to two molecules of glycine. The compound has superior bioavailability compared with magnesium oxide (the most common but poorly absorbed form), with absorption rates approaching 80 percent in clinical studies versus 4 to 12 percent for oxide. Glycine has independent anxiolytic and sleep-promoting effects through NMDA glycine site activity. The combination produces a magnesium product with low gastrointestinal disturbance and additional glycine benefits at the dosing required for elemental magnesium repletion.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Methylcobalamin

    Active vitamin B12

    The active methyl-form of vitamin B12 used for methylation support, particularly in subjects with cobalamin metabolism polymorphisms.

    Abstract

    Methylcobalamin is the active methyl-form of vitamin B12 (cobalamin), one of two coenzyme forms (the other being adenosylcobalamin). The compound is the cofactor for methionine synthase, which transfers methyl groups from 5-methyltetrahydrofolate to homocysteine to produce methionine and tetrahydrofolate. Methylcobalamin supplementation provides directly active B12 without requiring conversion from cyanocobalamin (the synthetic form most commonly used in supplementation), bypassing potential metabolic limitations.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Citalopram

    Selective serotonin reuptake inhibitor

    A racemic phthalane SSRI; the most selective for SERT over NET in clinical use.

    Abstract

    Citalopram (1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; CAS 59729-33-8; molecular formula C20H21FN2O; molecular weight 324.39) is a bicyclic phthalane SSRI developed at H. Lundbeck in Denmark and approved in Europe in 1989 and by the FDA in 1998 under the trade name Celexa. The compound is sold as the racemate; the (S)-enantiomer (escitalopram) accounts for essentially all SERT inhibitory activity, while the (R)-enantiomer is largely inactive but may attenuate the (S)-enantiomer’s binding through allosteric SERT interaction. SERT affinity ((S)-enantiomer): Ki approximately 1 nM; selectivity over NET and DAT exceeds 1000-fold, making citalopram the most selective SSRI in clinical use. Plasma half-life is 33 to 37 hours; hepatic metabolism via CYP2C19, CYP3A4, and CYP2D6 produces minimally active metabolites. Used as the canonical selective SERT inhibitor in mechanism studies and as a reference compound in SSRI structure-activity work.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.